Eli Lilly announced Phase 3 ATTAIN-1 trial results for orforglipron, an oral GLP-1 receptor agonist, showing significant weight loss in adults with obesity or overweight without diabetes
Smaller needles (2730 gauge) preserve stopper integrity better but require more draw time and generate higher shear forces on the peptide during aspiration
Statistical Analysis and Sample Size Statistical analysis was performed using GraphPad Prism Software 8 using one-way ANOVA for comparing more than two categories with Tukey corrections
2016;7: e142
$1,086+ retail Ozempic: $998 retail Mounjaro: $1,079 retail Trulicity, Saxenda, Victoza, Rybelsus: Prices vary Compounded semaglutide: $189/month (cash-pay only, not FDA approved) Non-GLP-1s: Membership may include certain non-GLP-1 medications only if the prescription is filled through Founds approved pharmacy partner
Based on this criterion, two cases were removed